Roche is to acquire Adheron Therapeutics for $105m upfront (+ $475m in milestones). The Swiss pharma giant will therefore be responsible for further developing Adheron’s Phase I asset SDP051, an anti-cadherin-11 monoclonal antibody that was fully humanised using Abzena's Composite Human Antibody technology. SDP051 has the potential to treat inflammatory/autoimmune diseases, such as rheumatoid arthritis and fibrotic disease (eg NASH), large target markets. We estimate that Abzena will re
09 Oct 2015
Pipeline candidate now in Roche’s hands
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pipeline candidate now in Roche’s hands
Roche is to acquire Adheron Therapeutics for $105m upfront (+ $475m in milestones). The Swiss pharma giant will therefore be responsible for further developing Adheron’s Phase I asset SDP051, an anti-cadherin-11 monoclonal antibody that was fully humanised using Abzena's Composite Human Antibody technology. SDP051 has the potential to treat inflammatory/autoimmune diseases, such as rheumatoid arthritis and fibrotic disease (eg NASH), large target markets. We estimate that Abzena will re